Vyteris regains rights to LidoSite for sale into physicians' offices

By Lisa Kerner

Erie, Pa., March 14 - Vyteris Holdings (Nevada), Inc. said it has regained the U.S. rights to LidoSite (Actyve Technology), an active transdermal analgesic, from B. Braun for sale into physicians' offices.

"Regaining rights to the U.S. physician office market for Actyve Technology is a significant first step in our focused efforts to create immediate commercialization of our Vyteris assets," chief executive officer Timothy J. McIntyre said in a company news release.

Vyteris said it plans to pursue co-marketing and sales partnerships with large pharmaceutical companies to reach specialty sub-markets, such as rheumatoid arthritis, blood collection, clinical testing and pediatrics.

In addition to regaining the U.S. rights to LidoSite for sale into physicians' offices, Vyteris also regained the rights to LidoSite for sale into the Japanese market, the company said.

Vyteris, based in Fair Lawn, N.J., developed the first electronically controlled transdermal delivery system to deliver drugs through the skin without needles.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.